HIPEC Combined With Sintilimab for Gastric Cancer With Peritoneal Metastasis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

December 31, 2027

Conditions
Gastric Cancer
Interventions
DRUG

HIPEC,anti-PD-1 antibody Sintilimab (Tyvyt®), Chemotherapy,Surgery

"1. HIPEC: HIPEC is performed after laparoscopic exploration, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgical exploration.~2. Chemotherapy(SOX) and anti-PD-1 antibody Sintilimab (Tyvyt®) treatment followed (4 cycles): SOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40-60 mg/m\^2 bid, po, day 1-14, every 3 weeks for a total of 4 cycles; Sintilimab (Tyvyt®) 200mg fixed dose every 3 weeks, for a total of 4 cycles.~3. Surgery: Imaging and secondary surgical exploration, assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases). For patients undergoing surgery, HIPEC for three cycles followed, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgery; For inoperable patients, continue to use standard chemotherapy of guidelines recommend.~4. After the surgery, continue to use standard adjuvant chemotherapy."

All Listed Sponsors
lead

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

OTHER

NCT05648487 - HIPEC Combined With Sintilimab for Gastric Cancer With Peritoneal Metastasis | Biotech Hunter | Biotech Hunter